Live Breaking News & Updates on Johnd Harkey Jr|Page 4

Stay updated with breaking news from Johnd harkey jr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dialectic Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas

Dialectic Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Johnd Harkey Jr , Joshua Sills , Robert Hromas , Cindy Walkerpeach , David Genecov , Seed Award For Product Development Research , Dialectic Therapeutics Inc , Cancer Prevention Research Institute Of Texas , Dean Of The Long School Medicine , Texas Company , Product Development , Prnewswire Dialectic Therapeutics Inc , University Of Florida Health , Ut Health San Antonio , Product Development Research Award , Cancer Prevention , Research Institute , Seed Award , Chief Executive , Dialectic Therapeutics , Product Development Officer , San Antonio , Long School , Daohong Zhou , Florida Health Cancer Center ,

Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216

Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
News provided by
Share this article
DALLAS, March 3, 2021 /PRNewswire/ Dialectic Therapeutics, Inc. (Dialectic
®), a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel
Antiapoptotic
Targeted
Degradation (APTaD™) technology. In pre-clinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy. ....

United States , Johnd Harkey Jr , Robert Hromas , David Genecov , Josh Sills , Seed Award For Product Development Research , University Of Florida Health , Dialectic Therapeutics Inc , Ut Health San Antonio , Drug Administration , Cancer Prevention Research Institute Of Texas , Dean Of The Long School Medicine , Dialectic Therapeutics , Seed Award , Cancer Prevention , Research Institute , Chief Executive , San Antonio , Long School , Daohong Zhou , Florida Health Cancer Center , Guangrong Zheng , Florida College , Product Development Research , ஒன்றுபட்டது மாநிலங்களில் , ஜோஷ் ஸில்ஸ் ,